Phase 4
Completed N=18
A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects
Healthy
Source: ClinicalTrials.gov NCT00666705 ↗
Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Jun 2009
Primary outcomePrimary: Maraviroc Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-time Profile Over the Dosing Interval (AUCτ) — 2551.9; 2971.6 ng.hr/mL
Summary
An open label study to evaluate an interaction between maraviroc and raltegravir in healthy subjects.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Maraviroc Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-time Profile Over the Dosing Interval (AUCτ) |
2551.9; 2971.6 | — |
| PRIMARY Maraviroc Pharmacokinetic (PK) Parameter: Maximum Concentration (Cmax) |
691.6; 851.4 | — |
| PRIMARY Raltegravir Pharmacokinetics (PK) Parameter: Area Under the Plasma Concentration-time Profile Over the Dosing Interval (AUCτ) |
6287.5; 9122.4 | — |
| PRIMARY Raltegravir Pharmacokinetics (PK) Parameter: Maximum Concentration (Cmax) |
2169.6; 3026.6 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy male and/or female subjects between 18 and 55 years of age.
Exclusion Criteria
- Evidence or history of clinically significant disease or clinical findings at screening
Data sourced from ClinicalTrials.gov (NCT00666705). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.